{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:16:23Z","timestamp":1780877783521,"version":"3.54.1"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Clin Immunol"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Combined immunodeficiency due to CARMIL2 mutations is a rare autosomal recessive primary immunodeficiency characterized by impaired T-cell activation and function, leading to diverse clinical manifestations. Fewer than 50 cases have been reported worldwide. We describe the clinical and genetic features of five patients from Palestine with homozygous CARMIL2 mutations, including the first documented case of recurrent visceral leishmaniasis associated with this gene defect. This retrospective case series was conducted using whole-exome sequencing to confirm the diagnosis. All patients exhibited significant immunologic symptoms, including chronic dermatitis, cutaneous warts, recurrent respiratory infections, and mucocutaneous candidiasis. Two developed cytomegalovirus-related disease. Genetic analysis revealed two novel homozygous variants: NM_001317026.3:c.1865\u00a0C\u2009&gt;\u2009T (p.Ala622Val) in four patients, and c.1973\u00a0C\u2009&gt;\u2009T (p.Ala658Val) in one. Notably, one adult male developed recurrent visceral leishmaniasis, an unusual presentation not previously reported in the context of CARMIL2 deficiency. Consanguinity was identified in two families. All patients required immunomodulatory therapy, and four were evaluated for hematopoietic stem cell transplantation. This case series underscores the clinical heterogeneity of CARMIL2-associated immunodeficiency and highlights the importance of genetic testing in patients with recurrent or atypical infections, particularly in populations with a high prevalence of consanguinity. The novel link to visceral leishmaniasis expands the known phenotypic spectrum of this condition.<\/jats:p>","DOI":"10.1007\/s10875-025-01956-1","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T02:13:16Z","timestamp":1762740796000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Combined Immunodeficiency Associated with Two Novel CARMIL2 Mutations: A Case Series"],"prefix":"10.1007","volume":"45","author":[{"given":"Saja I. Abu","family":"Ghannam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celina R.","family":"Andonie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tala Mahmoud","family":"Hamadna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lila H.","family":"Abu-Hilal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabee S.","family":"Adwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"key":"1956_CR1","doi-asserted-by":"crossref","unstructured":"Alazami AM, Al-Helale M, Alhissi S, Al-Saud B, Alajlan H, Monies D et al. Novel CARMIL2 mutations in patients with variable clinical dermatitis, infections, and combined immunodeficiency. Front Immunol [Internet]. 2018 [cited 2025 Apr 24];9. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/29479355\/","DOI":"10.3389\/fimmu.2018.00203"},{"key":"1956_CR2","doi-asserted-by":"crossref","unstructured":"Fischer A, Notarangelo LD, Neven B, Cavazzana M, Puck JM. Severe combined immunodeficiencies and related disorders. Nat Rev Dis Prim [Internet]. 2015 [cited 2025 Apr 24];1. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/27189259\/","DOI":"10.1038\/nrdp.2015.61"},{"key":"1956_CR3","doi-asserted-by":"crossref","unstructured":"Al-Herz W, Al-Mousa H. Combined immunodeficiency: the Middle East experience. J Allergy Clin Immunol [Internet]. 2013 [cited 2025 Apr 24];131:658\u201360. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/23321211\/","DOI":"10.1016\/j.jaci.2012.11.033"},{"key":"1956_CR4","doi-asserted-by":"crossref","unstructured":"Al-Saud B, Al-Mousa H, Al Gazlan S, Al-Ghonaium A, Arnaout R, Al-Seraihy A et al. Primary immunodeficiency diseases in Saudi Arabia: a tertiary care hospital experience over a period of three years (2010\u20132013). J Clin Immunol [Internet]. 2015 [cited 2025 Apr 24];35:651\u201360. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/26395454\/","DOI":"10.1007\/s10875-015-0197-6"},{"key":"1956_CR5","doi-asserted-by":"crossref","unstructured":"Zhu Y, Ye L, Huang H, Xu X, Liu Y, Wang J et al. Case report: primary immunodeficiency due to a novel mutation in CARMIL2 and its response to combined immunomodulatory therapy. Front Pediatr [Internet]. 2023 [cited 2025 Apr 24];10. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/36727012\/","DOI":"10.3389\/fped.2022.1042302"},{"key":"1956_CR6","unstructured":"Vinayagamoorthy V, Jain V, Nilay M, Shukla U, Reddy DVU. CARMIL-2 gene mutation: a novel cause of pediatric monogenic inflammatory bowel disease. Trop Gastroenterol [Internet]. 2023 [cited 2025 Apr 24];44:67\u20139. Available from: http:\/\/www.tropicalgastro.com\/articles\/44\/2\/CARMIL-2-Gene-Mutation.html"},{"key":"1956_CR7","doi-asserted-by":"crossref","unstructured":"Sorte HS, Osnes LT, Fevang B, Aukrust P, Erichsen HC, Backe PH et al. A potential founder variant in CARMIL2\/RLTPR in three Norwegian families with warts, molluscum contagiosum, and T-cell dysfunction. Mol Genet genomic Med [Internet]. 2016 [cited 2025 Apr 24];4:604\u201316. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/27896283\/","DOI":"10.1002\/mgg3.237"},{"key":"1956_CR8","doi-asserted-by":"crossref","unstructured":"Schober T, Magg T, Laschinger M, Rohlfs M, Linhares ND, Puchalka J et al. A human immunodeficiency syndrome caused by mutations in CARMIL2. Nat Commun [Internet]. 2017 [cited 2025 Apr 24];8. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/28112205\/","DOI":"10.1038\/ncomms14209"},{"key":"1956_CR9","doi-asserted-by":"crossref","unstructured":"Liang Y, Niederstrasser H, Edwards M, Jackson CE, Cooper JA. Distinct roles for CARMIL Isoforms in cell migration. Mol Biol Cell [Internet]. 2009 [cited 2025 Apr 24];20:5290. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC2793302\/","DOI":"10.1091\/mbc.e08-10-1071"},{"key":"1956_CR10","doi-asserted-by":"crossref","unstructured":"Bosa L, Batura V, Colavito D, Fiedler K, Gaio P, Guo C et al. Novel CARMIL2 loss-of-function variants are associated with pediatric inflammatory bowel disease. Sci Rep [Internet]. 2021 [cited 2025 Apr 24];11. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33723309\/","DOI":"10.1038\/s41598-021-85399-9"},{"key":"1956_CR11","unstructured":"Founder Effect -. an overview | ScienceDirect Topics [Internet]. [cited 2025 Oct 2]. Available from: https:\/\/www.sciencedirect.com\/topics\/biochemistry-genetics-and-molecular-biology\/founder-effect"},{"key":"1956_CR12","unstructured":"Founder Effect [Internet]. [cited 2025 Oct 2]. Available from: https:\/\/www.genome.gov\/genetics-glossary\/Founder-Effect"}],"container-title":["Journal of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-025-01956-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10875-025-01956-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-025-01956-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T15:47:45Z","timestamp":1777304865000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10875-025-01956-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1956"],"URL":"https:\/\/doi.org\/10.1007\/s10875-025-01956-1","relation":{},"ISSN":["0271-9142","1573-2592"],"issn-type":[{"value":"0271-9142","type":"print"},{"value":"1573-2592","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,10]]},"assertion":[{"value":"2 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Author(s) declare(s) that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"156"}}